Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission

JAMA Internal Medicine 2026 Open access

Read full text
Authors: Jennifer Leon, S. Sean Tu, Aaron S. Kesselheim, William B. Feldman
DOI: 10.1001/jamainternmed.2026.0980
Cited by: 1
References: 1

Abstract

This cohort study evaluates all products targeted by the Federal Trade Commission from 2023 to 2025 and analyzes how delistings have impacted periods of patent protection.

Fields of Study & Subjects

Intellectual Property and Patents Pharmaceutical Economics and Policy Innovation Policy and R&D

Publication details

Journal / source
JAMA Internal Medicine
Publisher
American Medical Association (AMA)
Volume
186
Issue
7
Pages
898–898
Publication date
11 May 2026
Language
EN